hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06314451, orgStudyIdInfo id: HAS.22.11.035, briefTitle: Cross-condition Validation of the Steroid PRO, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-06-01, primaryCompletionDateStruct date: 2024-05-31, completionDateStruct date: 2024-05-31, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: University of the West of England, class: OTHER, collaborators name: Johns Hopkins University, collaborators name: University of Pittsburgh, descriptionModule briefSummary: Testing a questionnaire about treatment with steroids for skin, lung or gastric conditions, conditionsModule conditions: Inflammatory Disease, conditions: Immune System Disorder, conditions: Gastrointestinal Diseases, conditions: Dermatologic Disease, conditions: Respiratory Disease, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Cognitive Interview, outcomesModule primaryOutcomes measure: Steroid PRO, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of the West of England, status: RECRUITING, city: Bristol, zip: BS2 8HW, country: United Kingdom, contacts name: Joanna C Robson, role: CONTACT, phone: 01173427417, email: Jo.Robson@uwe.ac.uk, geoPoint lat: 51.45523, lon: -2.59665, hasResults: False
protocolSection identificationModule nctId: NCT06314438, orgStudyIdInfo id: STUDY00017189, secondaryIdInfos id: UL1TR002319, type: NIH, link: https://reporter.nih.gov/quickSearch/UL1TR002319, briefTitle: Culturally-Responsive Curriculum for Caregivers With Children at Autism Likelihood, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-12-15, primaryCompletionDateStruct date: 2024-03-15, completionDateStruct date: 2024-03-15, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: University of Washington, class: OTHER, collaborators name: National Center for Advancing Translational Sciences (NCATS), descriptionModule briefSummary: The goal of this clinical trial is to examine how helpful and relevant the Family Care Project workbook is for families from culturally and linguistically diverse backgrounds who have a young child at autism likelihood. The main questions this trial aims to answer are:* Is the Family Care Project workbook useful for families?* Is the Family Care Project workbook easy to use?* Can the Family Care Project be implemented by non-profit workers who do not have health backgrounds?Participants will complete surveys that elicit their feedback on their use of the workbook., conditionsModule conditions: Autism, conditions: Development Delay, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 41, type: ACTUAL, armsInterventionsModule interventions name: Family Care Project, outcomesModule primaryOutcomes measure: Staff Training Feedback Survey of Implementation Properties (self-report), primaryOutcomes measure: Staff Competence in Assisting Families with Children at-autism Likelihood Survey (self-report), primaryOutcomes measure: The Maternal Self-Efficacy Scale Questionnaire, primaryOutcomes measure: Caregiver Knowledge and Use of Behaviors that Support Children at autism-likelihood Survey, primaryOutcomes measure: Current Services Utilized by Families to Support Children at autism-likelihood Survey, primaryOutcomes measure: Family Care Project Feedback Survey of Implementation Properties, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mother Africa, city: Kent, state: Washington, zip: 98032, country: United States, geoPoint lat: 47.38093, lon: -122.23484, hasResults: False
protocolSection identificationModule nctId: NCT06314425, orgStudyIdInfo id: IRB_20240714, briefTitle: Zirconia Implants: Practice-based Evidence, acronym: SDS, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-28, primaryCompletionDateStruct date: 2024-05, completionDateStruct date: 2025-12, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Swiss Dental Solutions, class: INDUSTRY, collaborators name: VISTA Institute for Therapeutic Innovations, descriptionModule briefSummary: This study is a prospective case series clinical study to examine the effectiveness of Ceramic dental implants manufactured by Swiss Dental Solutions (SDS). Participants with an indication from the dentist for teeth extraction and replacement are invited to participate in this study. Participating in this study will involve the use of dental implants manufactured by Swiss Dental Solutions (SDS zirconia dental implants), submission of the case data, including pre-operative information, intra-operative details, and post-operative follow-up data, to the study site and its collaborating partners.The SDS zirconia dental implants used in this research are FDA cleared devices that are available for dental treatments., conditionsModule conditions: Dental Implants, conditions: Ceramic Implant, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Immediate dental implants placements on fresh sockets after tooth extraction, outcomesModule primaryOutcomes measure: Cumulative Survival Rate (CSR), secondaryOutcomes measure: Marginal Bone Loss (MBL), otherOutcomes measure: Pink Esthetic Score (PES), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Brighton Periodontal & Implant Dental Group, status: RECRUITING, city: Woodland Hills, state: California, zip: 91367, country: United States, contacts name: Homayoun Zadeh, PhD, DDS, role: CONTACT, phone: 818-703-7733, email: homazadeh@gmail.com, contacts name: Etyene Schnurr, PhD, DDM, role: CONTACT, phone: 0797213110, email: etyene.schnurr@swiss-biohealth.com, geoPoint lat: 34.16834, lon: -118.60592, hasResults: False
protocolSection identificationModule nctId: NCT06314412, orgStudyIdInfo id: 24C211, briefTitle: Transcutaneous Posterior Tibial Nerve Stimulation in Patients With Multiple Sclerosis Related Urge Incontinence, acronym: SANS-REHAB, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-02-13, primaryCompletionDateStruct date: 2025-04, completionDateStruct date: 2025-07, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Istituto Auxologico Italiano, class: OTHER, descriptionModule briefSummary: Recently, several studies have investigated the safety and efficacy of the Stoller afferent nerve stimulation (SANS) treatment in Multiple Sclerosis (MS) patients. However, because of the differences among the published protocols (percutaneous versus transcutaneous stimulation, stimulation site, total number of sessions), and the absence of data on the duration of the effect, this treatment is not yet currently included in the rehabilitation programs. The present study aims at evaluating the efficacy of a protocol of SANS in the short- and medium-term follow-up.The efficacy of the proposed stimulation protocol on the physiological parameters of bladder function will be also investigated., conditionsModule conditions: Multiple Sclerosis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Stoller's Afferent Nerve Stimulation (SANS), outcomesModule primaryOutcomes measure: Measure of variation of incontinence., primaryOutcomes measure: Measure of variation of urinary urgency, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Istituto Auxologico Italiano, status: RECRUITING, city: Milan, zip: 20122, country: Italy, contacts name: Laura Perucca, MD, role: CONTACT, phone: +3902619116247, email: l.perucca@auxologico.it, contacts name: Nicole Bompani, MD, role: CONTACT, phone: +3902619116151, email: n.bompani@auxologico.it, geoPoint lat: 45.46427, lon: 9.18951, hasResults: False
protocolSection identificationModule nctId: NCT06314399, orgStudyIdInfo id: 2023-18, secondaryIdInfos id: DVO005 2555-CV1837, type: OTHER, domain: Universidad del Rosario Research Ethics Committee, briefTitle: Predictive Factors Associated to Bile Cultures and Antibiogram Resistance in Patients With Laparoscopic Cholecystectomy, acronym: BACILO, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-12, completionDateStruct date: 2026-06, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Hospital Universitario Mayor Méderi, class: OTHER, collaborators name: Universidad del Rosario, descriptionModule briefSummary: The BACILO study was designed with the objective of having robust data on local epidemiological bacterial colonisation information on bile cultures with patients taken to laparoscopic cholecystectomy in our institution to find which predictive factors are associated with culture positivity and antibiotic resistance patterns. Secondary endpoints include evaluating demographical, clinical and surgical variables and establishing comparison between both positive and negative bile cultures and between antibiotic sensitive and resistant microorganism strain isolations., conditionsModule conditions: Biliary Infection, conditions: Antibiotic Resistant Strain, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 703, type: ESTIMATED, armsInterventionsModule interventions name: Bile culture and phenotypic antibiogram resistance test, outcomesModule primaryOutcomes measure: Bile culture positivity, primaryOutcomes measure: Phenotypical antibiogram resistance, secondaryOutcomes measure: Microbial characteristics, secondaryOutcomes measure: Bile culture and antibiotic resistance relationship, secondaryOutcomes measure: Demographical and clinical characteristics, secondaryOutcomes measure: Surgical characteristics and outcomes, secondaryOutcomes measure: Determination of predictive factors (age, diabetes mellitus, choledocholithiasis / ERCP, C-reactive protein, cholecystitis and Tokyo guidelines severity of cholecystitis), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06314373, orgStudyIdInfo id: HSK39775-101/201, briefTitle: A Study for HSK39775 in Participants With Solid Tumors, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-07, primaryCompletionDateStruct date: 2028-02-01, completionDateStruct date: 2028-09-01, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Xizang Haisco Pharmaceutical Co., Ltd, class: INDUSTRY, descriptionModule briefSummary: This research is designed to determine if HSK39775 is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors., conditionsModule conditions: Advanced Solid Tumors, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NON_RANDOMIZED, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 243, type: ESTIMATED, armsInterventionsModule interventions name: HSK39775 Monotherapy, outcomesModule primaryOutcomes measure: AE/SAE, primaryOutcomes measure: DLT, primaryOutcomes measure: MTD/MAD, secondaryOutcomes measure: Maximum Plasma Concentration [Cmax], secondaryOutcomes measure: Area Under Curve[AUC], secondaryOutcomes measure: Time to maximum observed concentration [Tmax], secondaryOutcomes measure: Elimination half-life [t1/2], secondaryOutcomes measure: Overall Response Rate (ORR) per RECIST V1.1, secondaryOutcomes measure: Progression Free Survival, secondaryOutcomes measure: Time To Response, secondaryOutcomes measure: Disease Control Rate, secondaryOutcomes measure: Best percentage change in target lesion, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fundan University Shanghai Cancer Center, status: RECRUITING, city: Shanghai, state: Shanghai, zip: 200032, country: China, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06314347, orgStudyIdInfo id: gibtuipekkirmaci, briefTitle: Reference Value of Figure of 8 Walk Test, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2024-10-30, completionDateStruct date: 2024-11-30, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Gaziantep Islam Science and Technology University, class: OTHER, descriptionModule briefSummary: The aim of the study is to determine the reference values of the Figure 8 Walking Test in healthy adults., conditionsModule conditions: Healthy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 1000, type: ESTIMATED, armsInterventionsModule interventions name: Figure of 8 walk test, outcomesModule primaryOutcomes measure: Figure of 8 walk test, secondaryOutcomes measure: Age, secondaryOutcomes measure: gender, secondaryOutcomes measure: height, secondaryOutcomes measure: weight, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06314334, orgStudyIdInfo id: SHCA-NKT-202301, briefTitle: Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-03-04, primaryCompletionDateStruct date: 2026-12-30, completionDateStruct date: 2028-12-30, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Fudan University, class: OTHER, descriptionModule briefSummary: Extranodal NK/T-cell lymphoma, nasal type (NKTCL) is a common malignant tumor in East Asian populations, often starting in the nasal cavity and spreading to other organs. Associated with EBV infection, NKTCL is aggressive. Early-stage patients typically receive chemo and radiotherapy, with promising outcomes. Recent studies show the potential of immune checkpoint inhibitors in NKTCL treatment. However, optimal treatment sequencing and efficacy remain unclear. This study aims to compare three strategies: (A) Pegaspargase with Sintilimab and radiotherapy; (B) chemo then radiotherapy (PGemOx); (C) sandwich chemoradiotherapy (GELAD). The goal is to identify the best treatment based on 24-month progression-free survival., conditionsModule conditions: Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Participants were stratified according to the NRI prognostic index obtained from the baseline assessment (NRI \<2, NRI ≥2) and randomly assigned to three groups receiving different experimental treatments.Group A (synchronous treatment group) received 4 cycles of Sintilimab combined with pegaspargase therapy. Concurrently, they received radiotherapy treatment. Group B (sequential treatment group) received 4 cycles of the PGEMOX regimen chemotherapy with sequential radiotherapy.Group C (sandwiched radiotherapy group) received 2 cycles of the GELAD regimen chemotherapy initially, followed by radiotherapy and another two cycles GELAD chemotherapy., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 210, type: ESTIMATED, armsInterventionsModule interventions name: Sintilimab+Pegaspargase, interventions name: P-GemOx, interventions name: GELAD, interventions name: IMRT, outcomesModule primaryOutcomes measure: PFS24, secondaryOutcomes measure: ORR, secondaryOutcomes measure: OS, secondaryOutcomes measure: EFS, secondaryOutcomes measure: TRAE, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fudan University Shanghai Cancer Center, status: RECRUITING, city: Shanghai, state: Shanghai, zip: 200032, country: China, contacts name: Rong Tao, MD, role: CONTACT, phone: 8621-64175590, email: rtao@shca.org.cn, contacts name: Chuanxu Liu, MD, role: CONTACT, phone: 8621-64175590, email: liuchuanxu@shca.org.cn, contacts name: Rong Tao, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06314321, orgStudyIdInfo id: 2021-K151-01, briefTitle: The Effect of Baduanjin on Shoulder Function in Maintenance Hemodialysis Patients, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-01-01, primaryCompletionDateStruct date: 2023-06-30, completionDateStruct date: 2024-02-20, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Affiliated Hospital of Nantong University, class: OTHER, descriptionModule briefSummary: The aim of this study is to examine the effect of 18-month Baduanjin exercise on shoulder joint function in maintenance hemodialysis (MHD) patients. 60 MHD patients aged 18-75 will included in this study and randomly divided into two groups (intervention group and control group). The intervention group will be led by a professional person and underwent Baduanjin exercise three times a week before hemodialysis. The control group maintained routine treatment and daily activities., conditionsModule conditions: Hemodialysis Complication, conditions: Shoulder Joint Disorder, conditions: CKD-MBD, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ACTUAL, armsInterventionsModule interventions name: Baduanjin exercise, outcomesModule primaryOutcomes measure: Shoulder joint function score, primaryOutcomes measure: Shoulder joint internal rotation function, primaryOutcomes measure: Muscle strength measurement, primaryOutcomes measure: Area of biceps brachii muscle, secondaryOutcomes measure: Changes in the Short Form-36 (SF-36) and European Quality of Life Five Dimension（EQ-5D-5L）, secondaryOutcomes measure: Changes in the Hospital Anxiety and Depression Scale （HADS）, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Affiliated Hospital of Nantong University, city: Nantong, state: Jiangsu, zip: 226000, country: China, geoPoint lat: 32.03028, lon: 120.87472, documentSection largeDocumentModule largeDocs typeAbbrev: Prot_SAP, hasProtocol: True, hasSap: True, hasIcf: False, label: Study Protocol and Statistical Analysis Plan, date: 2021-11-30, uploadDate: 2024-03-12T09:17, filename: Prot_SAP_000.pdf, size: 148387, largeDocs typeAbbrev: ICF, hasProtocol: False, hasSap: False, hasIcf: True, label: Informed Consent Form, date: 2021-11-30, uploadDate: 2024-03-12T09:19, filename: ICF_001.pdf, size: 165056, hasResults: False
protocolSection identificationModule nctId: NCT06314295, orgStudyIdInfo id: BeijingH-WF, briefTitle: Automated Echocardiographic Detection of Coronary Artery Disease Using Artificial Intelligence Methods, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-11, primaryCompletionDateStruct date: 2026-03-11, completionDateStruct date: 2026-04-11, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Beijing Hospital, class: OTHER_GOV, descriptionModule briefSummary: The incidence rate and mortality of coronary artery disease are increasing year by year. Exploring non-invasive, accurate, and widely applicable methods to screen and diagnosis is of great significance. New ultrasound techniques, such as non-invasive myocardial work, have been proven to be superior to traditional ultrasound techniques in screening and diagnosis. However, diagnostic analysis based on ultrasound video images is time-consuming and subjective. The progress of artificial intelligence technology in fully automated quantitative evaluation of video images provides the possibility for computer-aided design screening and diagnosis. At present, the application of artificial intelligence in computer-aided design is a cutting-edge issue in the field of cardiovascular disease research. The application of artificial intelligence technology in the construction of computer-aided diagnostic models based on ultrasound video images is still in its early stages., conditionsModule conditions: Coronary Artery Disease, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 1500, type: ESTIMATED, outcomesModule primaryOutcomes measure: Different coronary angiography results, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06314282, orgStudyIdInfo id: D3461R00072, briefTitle: INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use, acronym: INTERSTELLAR, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-30, primaryCompletionDateStruct date: 2027-08-31, completionDateStruct date: 2027-08-31, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: AstraZeneca, class: INDUSTRY, descriptionModule briefSummary: INTERSTELLAR study will generate critical prospective real-world evidence on the benefits of adding Anifrolumab to standard of care treatment for SLE in routine clinical practice, to inform physicians, payers and patients. The study will use clinical assessments that are relevant for SLE-treating physicians in routine clinical practice, as well as introduce a specific measure for skin manifestations to affirm the potency of anifrolumab in treating SLE-related skin manifestations. The study will use standardized objectives, inclusion/exclusion criteria and outcome measures across all countries participating in this study including GCC (Qatar, KSA), Mexico, CAMCAR (Costa Rica, Panama, Dominican Republic), Colombia, Argentina, Taiwan, and Egypt, and any other countries that may be included in the study, in order to facilitate a comparison and analysis across all countries included in this study., conditionsModule conditions: Systemic Lupus Erythematosus (SLE), designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 200, type: ESTIMATED, outcomesModule primaryOutcomes measure: PGA, primaryOutcomes measure: SLEDAI-2K, primaryOutcomes measure: CLASI, primaryOutcomes measure: FACIT-Fatigue, primaryOutcomes measure: LupusQoL, primaryOutcomes measure: EQ-5D-5L, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False